Immunitas Therapeutics’ $58 Million Series B Financing Round

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Immunitas Therapeutics on the deal. Immunitas Therapeutics, an immuno-oncology biotech company, announced its $58 million Series B financing round. The round...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here